| CVSS Meta Temp Score | Current Exploit Price (≈) | CTI Interest Score |
|---|---|---|
| 6.2 | $5k-$25k | 0.00 |
Summary
A vulnerability was found in IBM Aspera. It has been rated as critical. Impacted is an unknown function of the component SOAP API. Performing a manipulation results in command injection. This vulnerability was named CVE-2020-4432. The attack may be initiated remotely. There is no available exploit.
Details
A vulnerability, which was classified as critical, was found in IBM Aspera (version unknown). This affects an unknown function of the component SOAP API. The manipulation with an unknown input leads to a command injection vulnerability. CWE is classifying the issue as CWE-77. The product constructs all or part of a command using externally-influenced input from an upstream component, but it does not neutralize or incorrectly neutralizes special elements that could modify the intended command when it is sent to a downstream component. This is going to have an impact on confidentiality, integrity, and availability. The summary by CVE is:
Certain IBM Aspera applications are vulnerable to command injection after valid authentication, which could allow an attacker with intimate knowledge of the system to execute commands in a SOAP API. IBM X-Force ID: 180810.
The weakness was presented 06/10/2020 (Website). The advisory is shared at exchange.xforce.ibmcloud.com. This vulnerability is uniquely identified as CVE-2020-4432 since 12/30/2019. The exploitability is told to be difficult. It is possible to initiate the attack remotely. The successful exploitation requires a authentication. Neither technical details nor an exploit are publicly available. The price for an exploit might be around USD $5k-$25k at the moment (estimation calculated on 06/11/2020). It is expected to see the exploit prices for this product increasing in the near future.MITRE ATT&CK project uses the attack technique T1202 for this issue.
There is no information about possible countermeasures known. It may be suggested to replace the affected object with an alternative product.
See VDB-156514, VDB-156515, VDB-156516 and VDB-156517 for similar entries. Several companies clearly confirm that VulDB is the primary source for best vulnerability data.
Product
Vendor
Name
License
Website
- Vendor: https://www.ibm.com/
CPE 2.3
CPE 2.2
CVSSv4
VulDB Vector: 🔍VulDB Reliability: 🔍
CVSSv3
VulDB Meta Base Score: 6.2VulDB Meta Temp Score: 6.2
VulDB Base Score: 5.0
VulDB Temp Score: 5.0
VulDB Vector: 🔍
VulDB Reliability: 🔍
NVD Base Score: 7.5
NVD Vector: 🔍
CVSSv2
| AV | AC | Au | C | I | A |
|---|---|---|---|---|---|
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| Vector | Complexity | Authentication | Confidentiality | Integrity | Availability |
|---|---|---|---|---|---|
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
VulDB Base Score: 🔍
VulDB Temp Score: 🔍
VulDB Reliability: 🔍
Exploiting
Class: Command injectionCWE: CWE-77 / CWE-74 / CWE-707
CAPEC: 🔍
ATT&CK: 🔍
Physical: No
Local: No
Remote: Yes
Availability: 🔍
Status: Not defined
EPSS Score: 🔍
EPSS Percentile: 🔍
Price Prediction: 🔍
Current Price Estimation: 🔍
| 0-Day | Unlock | Unlock | Unlock | Unlock |
|---|---|---|---|---|
| Today | Unlock | Unlock | Unlock | Unlock |
Threat Intelligence
Interest: 🔍Active Actors: 🔍
Active APT Groups: 🔍
Countermeasures
Recommended: no mitigation knownStatus: 🔍
0-Day Time: 🔍
Timeline
12/30/2019 🔍06/10/2020 🔍
06/11/2020 🔍
10/24/2020 🔍
Sources
Vendor: ibm.comAdvisory: exchange.xforce.ibmcloud.com
Status: Not defined
Confirmation: 🔍
CVE: CVE-2020-4432 (🔍)
GCVE (CVE): GCVE-0-2020-4432
GCVE (VulDB): GCVE-100-156513
X-Force: 180810
See also: 🔍
Entry
Created: 06/11/2020 12:07Updated: 10/24/2020 08:03
Changes: 06/11/2020 12:07 (39), 06/11/2020 12:12 (11), 10/24/2020 07:55 (1), 10/24/2020 08:03 (1)
Complete: 🔍
Cache ID: 216::103
Several companies clearly confirm that VulDB is the primary source for best vulnerability data.
No comments yet. Languages: en.
Please log in to comment.